Patents by Inventor Scott David Barnhart

Scott David Barnhart has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240024288
    Abstract: Disclosed herein are methods of administering relatively high doses of dexmedetomidine or a pharmaceutically acceptable salt thereof to a human subject, without also inducing significant sedation. The disclosed methods are particularly suitable for the treatment of agitation, especially when associated with neurodegenerative and/or neuropsychiatric diseases such as schizophrenia, bipolar illness such as bipolar disorder or mania, dementia, depression, or delirium.
    Type: Application
    Filed: July 17, 2020
    Publication date: January 25, 2024
    Inventors: Vasukumar KAKUMANU, David Christian HANLEY, Frank YOCCA, Chetan Dalpatbhai LATHIA, Scott David BARNHART, Lavanya RAJACHANDRAN, Robert RISINGER
  • Publication number: 20230390190
    Abstract: Disclosed herein is a self-supporting, dissolvable, film containing dexmedetomidine or a pharmaceutically acceptable salt thereof. The film is administered orally to treat various conditions, particularly agitation, by transmucosal delivery of the active agent.
    Type: Application
    Filed: August 11, 2023
    Publication date: December 7, 2023
    Inventors: Vasukumar KAKUMANU, David Christian HANLEY, Frank YOCCA, Chetan Dalpatbhai LATHIA, Scott David BARNHART
  • Publication number: 20230381099
    Abstract: Disclosed herein is a self-supporting, dissolvable, film containing dexmedetomidine or a pharmaceutically acceptable salt thereof. The film is administered orally to treat various conditions, particularly agitation, by transmucosal delivery of the active agent.
    Type: Application
    Filed: August 11, 2023
    Publication date: November 30, 2023
    Inventors: Vasukumar KAKUMANU, David Christian HANLEY, Frank YOCCA, Chetan Dalpatbhai LATHIA, Scott David BARNHART
  • Patent number: 11806429
    Abstract: Disclosed herein is a self-supporting, dissolvable, film containing dexmedetomidine or a pharmaceutically acceptable salt thereof. The film is administered orally to treat various conditions, particularly agitation, by transmucosal delivery of the active agent.
    Type: Grant
    Filed: January 20, 2022
    Date of Patent: November 7, 2023
    Assignee: BioXcel Therapeutics, Inc.
    Inventors: Vasukumar Kakumanu, David Christian Hanley, Frank Yocca, Chetan Dalpatbhai Lathia, Scott David Barnhart
  • Publication number: 20230140624
    Abstract: Disclosed herein is a self-supporting, dissolvable, film containing dexmedetomidine or a pharmaceutically acceptable salt thereof. The film is administered orally to treat various conditions, particularly agitation, by transmucosal delivery of the active agent.
    Type: Application
    Filed: December 20, 2022
    Publication date: May 4, 2023
    Inventors: Vasukumar KAKUMANU, David Christian HANLEY, Frank YOCCA, Chetan Dalpatbhai LATHIA, Scott David BARNHART
  • Publication number: 20230118091
    Abstract: Disclosed herein are methods of administering relatively high doses of dexmedetomidine or a pharmaceutically acceptable salt thereof to a human subject, without also inducing significant sedation. The disclosed methods are particularly suitable for the treatment of agitation, especially when associated with neurodegenerative and/or neuropsychiatric diseases such as schizophrenia, bipolar illness such as bipolar disorder or mania, dementia, depression, or delirium.
    Type: Application
    Filed: November 23, 2022
    Publication date: April 20, 2023
    Applicants: BioXcel Therapeutics, Inc., ARx, LLC
    Inventors: Vasukumar KAKUMANU, David Christian HANLEY, Frank YOCCA, Chetan Dalpatbhai LATHIA, Scott David BARNHART, Lavanya RAJACHANDRAN, Robert RISINGER
  • Patent number: 11559484
    Abstract: Disclosed herein is a self-supporting, dissolvable, film containing dexmedetomidine or a pharmaceutically acceptable salt thereof. The film is administered orally to treat various conditions, particularly agitation, by transmucosal delivery of the active agent.
    Type: Grant
    Filed: November 24, 2020
    Date of Patent: January 24, 2023
    Assignees: BioXcel Therapeutics, Inc., ARx, LLC
    Inventors: Vasukumar Kakumanu, David Christian Hanley, Frank Yocca, Chetan Dalpatbhai Lathia, Scott David Barnhart
  • Patent number: 11517524
    Abstract: Disclosed herein is a self-supporting, dissolvable, film containing dexmedetomidine or a pharmaceutically acceptable salt thereof. The film is administered orally to treat various conditions, particularly agitation, by transmucosal delivery of the active agent.
    Type: Grant
    Filed: December 23, 2021
    Date of Patent: December 6, 2022
    Assignees: BioXcel Therapeutics, Inc., ARx, LLC
    Inventors: Vasukumar Kakumanu, David Christian Hanley, Frank Yocca, Chetan Dalpatbhai Lathia, Scott David Barnhart
  • Patent number: 11497711
    Abstract: Disclosed herein is a self-supporting, dissolvable, film containing dexmedetomidine or a pharmaceutically acceptable salt thereof. The film is administered orally to treat various conditions, particularly agitation, by transmucosal delivery of the active agent.
    Type: Grant
    Filed: December 23, 2021
    Date of Patent: November 15, 2022
    Assignees: BioXcel Therapeutics, Inc., ARx, LLC
    Inventors: Vasukumar Kakumanu, David Christian Hanley, Frank Yocca, Chetan Dalpatbhai Lathia, Scott David Barnhart
  • Patent number: 11478422
    Abstract: Disclosed herein is a self-supporting, dissolvable, film containing dexmedetomidine or a pharmaceutically acceptable salt thereof. The film is administered orally to treat various conditions, particularly agitation, by transmucosal delivery of the active agent.
    Type: Grant
    Filed: July 17, 2020
    Date of Patent: October 25, 2022
    Assignees: BioXcel Therapeutics, Inc., ARx, LLC
    Inventors: Vasukumar Kakumanu, David Christian Hanley, Frank Yocca, Chetan Dalpatbhai Lathia, Scott David Barnhart
  • Patent number: 11419769
    Abstract: The invention features sublingual film formulations of dopamine agonists and methods of treating Parkinson's disease, tremors, restless leg syndrome, sexual dysfunction, and depressive disorders therewith.
    Type: Grant
    Filed: May 10, 2019
    Date of Patent: August 23, 2022
    Assignee: Sunovion Pharmaceuticals Inc.
    Inventors: Nathan John Bryson, Anthony John Giovinazzo, Scott David Barnhart, Michael Clinton Koons
  • Publication number: 20220160629
    Abstract: Disclosed herein is a self-supporting, dissolvable, film containing dexmedetomidine or a pharmaceutically acceptable salt thereof. The film is administered orally to treat various conditions, particularly agitation, by transmucosal delivery of the active agent.
    Type: Application
    Filed: December 23, 2021
    Publication date: May 26, 2022
    Inventors: Vasukumar Kakumanu, David Christian Hanley, Frank Yocca, Chetan Dalpatbhai Lathia, Scott David Barnhart
  • Publication number: 20220142918
    Abstract: Disclosed herein is a self-supporting, dissolvable, film containing dexmedetomidine or a pharmaceutically acceptable salt thereof. The film is administered orally to treat various conditions, particularly agitation, by transmucosal delivery of the active agent.
    Type: Application
    Filed: January 20, 2022
    Publication date: May 12, 2022
    Inventors: Vasukumar KAKUMANU, David Christian HANLEY, Franks YOCCA, Chetan Dalpatbhai LATHIA, Scott David BARNHART
  • Publication number: 20220110864
    Abstract: Disclosed herein is a self-supporting, dissolvable, film containing dexmedetomidine or a pharmaceutically acceptable salt thereof. The film is administered orally to treat various conditions, particularly agitation, by transmucosal delivery of the active agent.
    Type: Application
    Filed: December 23, 2021
    Publication date: April 14, 2022
    Inventors: Vasukumar KAKUMANU, David Christian Hanley, Frank Yocca, Chetan Dalpatbhai Lathia, Scott David Barnhart
  • Publication number: 20210205208
    Abstract: Methods and pharmaceutical unit dosage forms for treating Parkinson's disease in a subject (e.g., an “off” episode in a subject having Parkinson's disease) are described. The pharmaceutical unit dosage forms are films having a first portion including particles containing an acid addition salt of apomorphine and a second portion containing a pH neutralizing agent. The pharmaceutical unit dosage forms can be flexible and have toughness greater than 100 g×mm. The methods can involve administering to a subject having Parkinson's disease a therapeutic dose sufficient to produce an apomorphine plasma concentrate of at least 2.64 ng/mL within 45 minutes after the administration. The subject may be identified as having low uptake, medium uptake, or high uptake of apomorphine administered via oral mucosa.
    Type: Application
    Filed: February 18, 2021
    Publication date: July 8, 2021
    Inventors: Scott David BARNHART, Michael Clinton KOONS, Madhu Sudan HARIHARAN, Jordan DUBOW, Thierry BILBAULT, Anthony John GIOVINAZZO
  • Patent number: 10959943
    Abstract: Methods and pharmaceutical unit dosage forms for treating Parkinson's disease in a subject (e.g., an “off” episode in a subject having Parkinson's disease) are described. The pharmaceutical unit dosage forms are films having a first portion including particles containing an acid addition salt of apomorphine and a second portion containing a pH neutralizing agent. The pharmaceutical unit dosage forms can be flexible and have toughness greater than 100 g×mm. The methods can involve administering to a subject having Parkinson's disease a therapeutic dose sufficient to produce an apomorphine plasma concentrate of at least 2.64 ng/mL within 45 minutes after the administration. The subject may be identified as having low uptake, medium uptake, or high uptake of apomorphine administered via oral mucosa.
    Type: Grant
    Filed: September 9, 2019
    Date of Patent: March 30, 2021
    Assignee: Sunovion Pharmaceuticals Inc.
    Inventors: Scott David Barnhart, Michael Clinton Koons, Madhu Sudan Hariharan, Jordan Dubow, Thierry Bilbault, Anthony John Giovinazzo
  • Publication number: 20210077388
    Abstract: Disclosed herein is a self-supporting, dissolvable, film containing dexmedetomidine or a pharmaceutically acceptable salt thereof. The film is administered orally to treat various conditions, particularly agitation, by transmucosal delivery of the active agent.
    Type: Application
    Filed: November 24, 2020
    Publication date: March 18, 2021
    Inventors: Vasukumar Kakumanu, David Christian Hanley, Frank Yocca, Chetan Dalpatbhai Lathia, Scott David Barnhart
  • Publication number: 20200345635
    Abstract: Disclosed herein is a self-supporting, dissolvable, film containing dexmedetomidine or a pharmaceutically acceptable salt thereof. The film is administered orally to treat various conditions, particularly agitation, by transmucosal delivery of the active agent.
    Type: Application
    Filed: July 17, 2020
    Publication date: November 5, 2020
    Inventors: Vasukumar KAKUMANU, David Christian HANLEY, Frank YOCCA, Chetan Dalpatbhai LATHIA, Scott David BARNHART
  • Patent number: 10792246
    Abstract: Disclosed herein is a self-supporting, dissolvable, film containing dexmedetomidine or a pharmaceutically acceptable salt thereof. The film is administered orally to treat various conditions, particularly agitation, by transmucosal delivery of the active agent.
    Type: Grant
    Filed: June 26, 2019
    Date of Patent: October 6, 2020
    Assignees: BIOXCEL THERAPEUTICS, INC., ARX, LLC
    Inventors: Vasukumar Kakumanu, David Christian Hanley, Frank Yocca, Chetan Dalpatbhai Lathia, Scott David Barnhart
  • Publication number: 20200069571
    Abstract: Methods and pharmaceutical unit dosage forms for treating Parkinson's disease in a subject (e.g., an “off” episode in a subject having Parkinson's disease) are described. The pharmaceutical unit dosage forms are films having a first portion including particles containing an acid addition salt of apomorphine and a second portion containing a pH neutralizing agent. The pharmaceutical unit dosage forms can be flexible and have toughness greater than 100 g×mm. The methods can involve administering to a subject having Parkinson's disease a therapeutic dose sufficient to produce an apomorphine plasma concentrate of at least 2.64 ng/mL within 45 minutes after the administration. The subject may be identified as having low uptake, medium uptake, or high uptake of apomorphine administered via oral mucosa.
    Type: Application
    Filed: September 9, 2019
    Publication date: March 5, 2020
    Inventors: Scott David BARNHART, Michael Clinton KOONS, Madhu Sudan HARIHARAN, Jordan DUBOW, Thierry BILBAULT, Anthony John GIOVINAZZO